The EPS miss and slowing U.S. revenue growth (unit growth of 13% but revenue only +3% due to mix) are concerning. Watch for Q2 revenue guidance of $20M, if achieved, it would imply ~5% YoY growth, still below the full-year 8% target. Monitor cash burn trajectory; at current rate, cash runway is ~3 quarters without additional financing.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 13 $0.9600entry
- T+1 · 6mo ago 0.00%α +0.00% · $0.9600
- T+5 · 6mo ago −10.42%α −9.26% · $0.8600
- T+20 · 5mo ago −5.00%α −4.39% · $0.9120
- T+60 · 3mo ago −9.39%α −13.82% · $0.8699
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
TELA Bio reported Q1 2026 revenue of $19.1M (+3% YoY), slightly above the $19.0M consensus, and an EPS of -$0.21 (GAAP), which is worse than the -$0.19 consensus estimate. The company reiterated full-year 2026 revenue guidance of at least 8% growth, but Q1 growth was only 3%, and net loss widened to $12.3M from $11.3M a year ago. The stock may face pressure from the EPS miss and decelerating revenue growth, partially offset by the reiterated guidance and European momentum.
Key Financial Metrics
Key Facts
- Q1 2026 revenue of $19.1M, +3% YoY (vs consensus $19.0M)
- GAAP EPS of -$0.21 vs consensus -$0.19 (miss of 10.5%)
- Net loss widened to $12.3M from $11.3M in Q1 2025
- Gross margin declined to 65.7% from 67.6% due to higher excess inventory charges
- Reiterated full-year 2026 revenue guidance of at least 8% growth
- Q2 2026 revenue guided to ~$20.0M
- Cash and equivalents of $39.5M, down from $50.8M at year-end 2025
- European revenue grew 41% YoY; U.S. revenue growth was modest due to product mix headwinds
Financial Impact
Revenue beat consensus by ~$0.1M (0.5%), but EPS missed by $0.02 (10.5%). Net loss increased $1.0M YoY.
Risk Factors
- Cash burn: $11.3M in Q1, leaving ~3.5 quarters of runway at current pace
- U.S. product mix headwinds pressuring revenue growth despite unit growth
- GAAP EPS miss of 10.5% vs consensus may disappoint investors
- Full-year 8% growth guidance requires acceleration from Q1's 3%
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293358 |
Track record
20 reports on TELA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $0.7610 Now $0.7620 +0.13% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.8200 Now $0.7620 −7.07% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.8201 Now $0.7620 −7.08% settles Nov 23
- Nov 10, 20266d ago S-3 Bearish 5/10 Entry $0.9418 Now $0.7620 +19.09% settles Nov 18
- Nov 10, 20266d ago Press Release Bearish 5/10 Entry $0.9418 Now $0.7620 +19.09% settles Nov 18
- Oct 27, 202620d ago Press Release Neutral 2/10 Entry $0.9760 to $0.8378 Now $0.7620 −21.93% ▼ −14.16% −13.45% vs SPY
- Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.07 to $1.10 Now $0.7620 −28.79% ▲ +2.34% +3.32% vs SPY
- Oct 5, 20266w ago 8-K Bullish 5/10 Entry $1.14 to $1.08 Now $0.7620 −33.16% ▼ −5.26% −5.69% vs SPY
- Aug 31, 202611w ago 8-K Mixed 6/10 Entry $0.7380 to $0.8301 Now $0.7620 +3.25% ▲ +12.48% +12.62% vs SPY
- Aug 10, 202614w ago 8-K Bearish 7/10 Entry $0.7900 to $0.6430 Now $0.7620 +3.54% ▲ +18.61% +18.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers